
ICCM Stock Forecast & Price Target
ICCM Analyst Ratings
Bulls say
Icecure Medical Ltd is positioned for positively impacting its topline sales in the first half of 2026, largely due to anticipated FDA marketing authorization for its ProSense cryoablation system for breast cancer in 2025. The successful De Novo clearance and encouraging results from the ICE3 trial underscore the efficacy of their liquid nitrogen-based technology as a minimally invasive treatment alternative, which may further enhance market adoption. Additionally, a narrower net loss of $3.6 million per share, compared to earlier estimates, reflects improved financial stability and operational efficiency that could support future growth prospects.
Bears say
IceCure Medical reported a revenue of $725K for 1Q25, reflecting a 2% year-over-year decline, which aligns closely with projections but indicates stagnation in sales. The company faces challenges in achieving commercial success for its cryoablation systems due to limited market size and increasing competition, particularly highlighted by weak performance in the Asian market. Additionally, the presence of dilution risk further complicates the financial outlook, raising concerns among investors about the sustainability and growth potential of the company's revenue streams.
This aggregate rating is based on analysts' research of Icecure Medical Ltd and is not a guaranteed prediction by Public.com or investment advice.
ICCM Analyst Forecast & Price Prediction
Start investing in ICCM
Order type
Buy in
Order amount
Est. shares
0 shares